Antioxidant efcts of Abexol in middle-aged and older subjects

Abexol effect on indicators of oxidative stress and quality of life in middle-aged and older subjects - Abe/P-01

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

RPCEC

Registry ID

RPCEC00000401

Enrollment

Registered

2022-03-20

Start date

2007-07-17

Completion date

Unknown

Last updated

2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Oxidative strees in middle-aged and older subject

Interventions

Group 1 Placebo (Control): Placebo, two tablets by oral route, one a day, for 12 weeks Group 2 Abexol (Experimental): Abexol (50 mg), two tablets by oral route, one a day, for 12 weeks

Dietary Supplements

Tablets

Administration, Oral

Abexol

Eligibility

Sex/Gender

All

Age

40 Years to 75 Years

Inclusion criteria

Inclusion criteria: Subjects who provided written informed consent for participating in the trial

Exclusion criteria

Exclusion criteria: Patients with: 1) Diagnosed thyroid 2) Hepatic and/or renal diseases active 3) Diagnosed cancer 4) Uncontrolled diabetes (fasting glucose a head 7) 5) Arterial hypertension (diastolic pressure a head 100 mmHg) 6) Values of blood indicators: ALT or AST a head 55 UI, creatinine a head 130 umol/L 7) Has suffered myocadial infarction, unstable angina, stroke, ATI, major surgery, within six months prior the study 8) Consuming antioxidant supplements or vitamins within the last 4 weeks prior the trial

Design outcomes

Primary

Measure	Time frame
1. Malondiialdehyde (MDA) (nmmol/MDA/mL). Measurement time: At baseline and 12 weeks (Significant decrease of values at the end of treatment respect baseline values and values of the placebo group) 2. Total Hydroperoxides (nmol/mg protein). Measurement time: At baseline and 12 weeks (Significant decrease of values at the end of treatment respect baseline values and values of the placebo group)	—

Secondary

Measure	Time frame
Total antioxidant status (mL whole blood). Measurement time: At baseline ans 12 weeks (Singnifican increase of values at the end of treatment respect baseline values and values of the placebo group)	—

Countries

Cuba

Contacts

Public ContactJulio Fernandez Travieso

Unit of Clinical Trials, National Centre for Scientific Research (CNIC)

julio.fernandez@cnic.cu

Outcome results

None listed

Source: RPCEC (via WHO ICTRP) · Data processed: Apr 4, 2026